The Theranos device associated with unreliable blood test results was called the Edison. It was marketed as a revolutionary analyzer that could run many tests from a finger-prick sample, but evidence later showed that its performance was far less capable and reliable than the company claimed.
Theranos used the Edison name for an early generation of its proprietary testing systems, also referred to in some contexts as the Theranos Sample Processing Unit. The company promoted the technology as faster, cheaper, and more accurate than conventional laboratory testing. In practice, many tests were run on modified commercial analyzers, and concerns emerged about dilution methods, quality control, and inconsistent results.
The problems affected patients as well as investors. Theranos eventually voided two years of Edison-related test results from 2014 and 2015, prompting corrected reports and regulatory scrutiny. The later miniLab was another Theranos device presented publicly, but it was not the machine most directly associated with the patient-testing controversy and invalidated results. That distinction makes Edison the standard quiz answer.